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background: Previous studies have indicated that peripheral circulating markers of inﬂammation are elevated in women with polycystic
ovary syndrome (PCOS), but thus far no studies concerning markers of inﬂammation in adipose tissue have been published. The aim of the
study was to investigate whether patients with PCOS display increased expression of inﬂammatory markers in adipose tissue.
methods: Twenty overweight patients with PCOS, 10 lean patients with PCOS and 20 overweight controls had subcutaneous fat biop-
sies and blood samples taken. Adipose tissue levels of mRNA of inﬂammatory markers were determined by use of real-time PCR.
results: Overweight patients with PCOS had higher relative adipose tissue chemokine ligand 2 (P , 0.01), and its cognate receptor
(P , 0.05), tumour necrosis factor-a (P , 0.001), interleukin (IL)-10 (P , 0.001) and IL-18 (P , 0.001) and the monocyte/macrophage
markers CD14 (P , 0.01) and CD163 (P , 0.01) mRNA levels compared with lean women with PCOS. There were no differences
between overweight patients with PCOS and overweight control subjects in this respect. Within the PCOS group, markers of adipose
tissue inﬂammation correlated signiﬁcantly with obesity-related metabolic disturbances, but when data were adjusted for age and BMI,
most correlations were lost.
conclusions: Overweight, rather than the PCOS diagnosis per se, appears to be the main explanatory variable for elevated adipose
tissue inﬂammation in patients with PCOS.
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Introduction
Polycystic ovary syndrome (PCOS) is one of the most common endo-
crine disorders, affecting 5–10% of women of child-bearing age (Kno-
chenhauer et al., 1998; Diamanti-Kandarakis et al., 1999; Asuncion
et al., 2000; Azziz et al., 2004; Lindholm et al., 2008). Women with
PCOS carry a number of risk markers for cardiovascular disease
(CVD), such as obesity, type 2 diabetes, hypertension and dyslipide-
mia, and these risk factors remain, even after adjustment for age
and BMI (Lo et al., 2006).
Obesity is a common feature of PCOS, with prevalence rates
varying between 38 and 88% (Barber et al., 2006). The elevated
metabolic risk proﬁle associated with obesity is, to a large extent,
dependent on body fat distribution. Central obesity is of importance
in the deﬁnition of the metabolic syndrome, and especially visceral
fat accumulation is associated with insulin resistance and CVD
(Despres and Lemieux, 2006).
Obesity is characterized by a systemic low-grade inﬂammatory
state that is thought to originate from the adipose tissue (Kershaw
and Flier, 2004). The adipose tissue is an active endocrine
organ that produces and releases hormones, pro- and anti-
inﬂammatory cytokines and chemoattractant cytokines (chemokines).
Pro-inﬂammatory molecules produced by the adipose tissue are pro-
posed to be active participants in the development of insulin
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(Mahadik et al., 2008).
Recently, it was reported that adipose tissue in obesity is character-
ized by macrophage inﬁltration, and that macrophages are an impor-
tant contributor to inﬂammation (Cancello and Clement, 2006). An
increased macrophage inﬁltration could be caused by different chemo-
kines thought to attract inﬂammatory cells to the adipose tissue. One
such example is chemokine (C-C motif) ligand 2 (CCL2) (also known
as monocyte chemoattractant protein-1, MCP-1) and its cognate
receptor chemokine receptor 2 (CCR2), both of which contribute
to systemic insulin resistance, macrophage inﬁltration and maintenance
of macrophages in the adipose tissue (Kershaw and Flier, 2004; Can-
cello and Clement, 2006).
In addition to increased macrophage inﬁltration, the expression and
release of pro-inﬂammatory cytokines, such as macrophage migration
inhibitory factor (MIF), tumour necrosis factor-a (TNF-a) and
interleukin-18 (IL-18), is increased in adipose tissue in the obese
(Hotamisligil et al., 1995; Bruun et al., 2007; Skopkova et al., 2007),
and there is strong evidence that the expanded adipose tissue mass
of the obese contributes, directly or indirectly, to the increased circu-
lating levels of inﬂammatory markers found in obese patients (Hotami-
sligil, 2006).
Circulating markers of inﬂammation, including MCP-1, MIF and high-
sensitive C-reactive protein (hs-CRP), are elevated in overweight
women with PCOS in comparison with weight-matched controls
(Diamanti-Kandarakis et al., 2006; Glintborg et al., 2009; Gonzalez
et al., 2009). However, thus far no studies concerning inﬂammatory
markers in adipose tissue have been conducted in patients with PCOS.
Our hypothesis was that overweight/obesity would be associated
with increased adipose tissue expression of inﬂammatory markers,
irrespective of a PCOS diagnosis.
Materials and Methods
Subjects
Twentyoverweightpatients withPCOS,10 leanpatientswith PCOSand20
overweightcontrolsubjectswereincludedattheDepartmentsofObstetrics
and Gynaecology at Uppsala University Hospital, Umea ˚ University Hospital
andSunderbyHospital,Sweden.AllpatientswithPCOSwererecruitedfrom
among patients seeking care for oligomenorrhoea and/or hirsutism at the
out-patient wards of the participating clinics. The overweight control sub-
jects were recruited by advertisement in local newspapers.
Overweight patients with PCOS and overweight control subjects had
BMI .27.0 kg/m
2, whereas lean patients with PCOS had BMI
,25.0 kg/m
2. The limit for BMI was chosen based on prior studies indi-
cating an increased insulin resistance already at BMI 27 kg/m
2 in patients
with PCOS (Gennarelli et al., 2000).
PCOS was deﬁned according to the Rotterdam criteria (Welt et al.,
2006). Two of the following three features had to be present for the
PCOS diagnosis (i) oligomenorrhoea with eight or fewer menstruations
in the previous 12 months or amenorrhoea (ii) clinical and/or biochemical
signs of hyperandrogenism such as testosterone . 2.7 nmol/l, elevated
dehydroepiandrosterone sulphate (.9.2 mmol/l), free androgen index
(FAI ≥5.0), or hirsutism (.7 on the Ferriman and Gallway scale) and
(iii) polycystic ovaries on ultrasound examination [.12 follicles 2–9 mm
diameter and/or increased ovarian volume (.10 ml)]. PCOS diagnosis
also implied that thyroid disease, adrenocortical dysfunction and hyperpro-
lactinemia were not present.
Control subjects had regular menstrual cycles (cycle length 25–31
days), normal androgen levels and no signs of polycystic ovaries on trans-
vaginal ultrasound.
Inclusion criteria for the study were conﬁrmed PCOS/control status
and age 18–40 years. Exclusion criteria for the study (all groups) were
obesity owing to organic disorder, presence of chronic illness and use of
hormonal treatments 6 months prior to inclusion in the study (including
combined oral contraceptives, progestagens, ovulatory stimulants, anti-
diabetics, cortisone, anti-inﬂammatory drugs, statins and anti-androgens).
The patients with PCOS and controls gave written informed consent
and the Independent Ethical Review Board at Uppsala University,
Sweden, approved the study.
Procedures before surgery
After overnight fasting, blood samples for glucose, insulin, triglycerides
(TG), cholesterol, hs-CRP, IL-18, CCL2, testosterone and sex hormone-
binding globulin (SHBG) were drawn between 08.00 and 08.30. The
blood samples were stored at 2208C until analysed. FAI was calculated
as testosterone (nmol/l)/SHBG (nmol/l) × 100, and homeostasis
model assessment of insulin resistance (HOMA-IR) as fasting serum
insulin (mU/l) × fasting serum glucose (mmol/l)/22.5 (Albareda et al.,
2000).
Height (to the nearest cm) and weight (to the nearest 200 g) was
measured in stockinged feet and light clothes using standardized equip-
ment. Waist circumference (to the nearest 0.5 cm) measurement was per-
formed midway between the lower rib margin and iliac crest. Hip
circumference (to the nearest 0.5 cm) was taken around the maximal
girth of the hips. Blood pressure was measured (average of three readings)
after 5 min rest, while seated.
Fat biopsies
Following local anaesthesia with prilocain (10 mg/ml) in the skin area to
the right of the umbilicus,  1.5 cm
2 of superﬁcial subcutaneous adipose
tissue was excised through a 1.5 cm incision. The fat biopsies were
placed into vials and snap frozen in liquid nitrogen and stored at 2708C
until assayed.
Blood analyses
TG, hs-CRP and glucose were analysed on an Architect ci8200 (Abbott
Laboratories, Abbott Park, IL, USA). The total imprecision (coefﬁcient
of variation, CV) of the instrument for the analytes were 1.1% at
0.9 mmol/l for TG, 0.8% at 8 mg/l for hs-CRP and 1.0% at 4.4 mmol/l
for glucose. Insulin, SHBG and testosterone were analysed on a Modular
E170 (Roche Diagnostics, Mannheim, Germany). The total CV of the
instrument for the analytes was 1.6% at 7.0 mU/l for insulin, 1.5% at
43 nmol/l for SHBG and 6.8% at 3.9 nmol/l for testosterone. Serum
levels of IL-18 (Human IL-18 ELISA kit, R&D Systems Abingdon, UK)
and CCL2 (Quantikine Human MCP-1, R&D Systems) were measured
using a commercially available immunoassay according to the instructions
from the manufacturer (Lettesjo et al., 2005). However, the wavelength
correction for CCL2 was set to 620 nm instead of 540 nm in all exper-
iments. The detection limit for IL-18 was ,12.5 pg/ml and the
minimum detectable concentration of CCL2 was ,5.0 pg/ml.
RNA extraction, reverse transcription and
real-time PCR
Total RNA was extracted from adipose biopsies using a RNeasyLipid
Tissue Mini Kit (QIAGEN, Hilden, Germany). The yield and purity of
RNA were determined by spectrophotometer (ND-1000 spectropho-
tometer, NanoDrop Technologies, Wilmington, DE9) and RNA integrity
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dium bromide. One microgram of total RNA was reverse transcribed,
using TaqMan RT reagents (High Capacity cDNA Reverse Transcription
kit, Applied Biosystems, Foster City, CA, USA) and RNase inhibitor
(Applied Biosystems) at a ﬁnal concentration of 1.0 U/ml. Subsequently,
speciﬁc mRNAs were run in duplicate on an ABI Prism 7900HT sequence
detection system (Applied Biosystems) using Taqman Universal PCR
Master Mix (Applied Biosystems). Ten inﬂammation-related genes were
included in the analysis, including the chemokine CCL2 and its receptor
CCR2; the pro-inﬂammatory cytokines MIF, TNF-a, IL-6 and IL-18; the
anti-inﬂammatory cytokine IL-10; the monocyte/macrophage
markers CD14 and CD163; and adiponectin. The following TaqMan
gene expression assays (Applied Biosystems) were used; CCL2
(Hs00234140_ml), CCR2 (Hs00356601_m1), MIF (Hs00236988_g1),
TNF-a (Hs00174128_m1), IL-6 (Hs00985639_m1), IL-10
(Hs00174086_m1), IL-18 (Hs999999040_ml), CD14 (Hs00169122_g1),
CD163 (Hs01016657_m1), adiponectin (Hs00605917_m1), low density
lipoprotein receptor-related protein 10 (LRP10: Hs00204094_ml), pepti-
dylprolyl isomerase A (cyclophilin A)(PPIA: Hs999999904_ml), as well
as acidic ribosomal phosphoprotein P0(RPLP0: Hs99999902_ml). The
parameter cycle threshold (Ct) is deﬁned as the cycle number at which
the ﬂuorescence intensity exceeds a ﬁxed threshold. Relative amounts of
mRNA for target genes were calculated using the comparative Ct
method (DDt). Reference genes were evaluated by running LRP10, PPIA
and RPLP0 on the full study cohort, and the NormFinder (Andersen
et al., 2004) algorithm identiﬁed RPLP0 as the best gene to use in normal-
ization. The expression of RPLP0 was thus used to normalize samples for
the amount of cDNA used per reaction.
Statistics
The power analysis was based on the assumption that the difference
between overweight patients with PCOS and overweight controls would
be 25% of the difference between lean and obese women (Hotamisligil
et al., 1995; Bruun et al., 2007). With this assumption, the study had
.85% power to detect differences in adipose tissue mRNA expression
between these two groups, given an a-error of 0.05. All variables were
log-transformed prior to statistical analyses unless normally distributed.
Comparisons between groups were made using one-way analysis of
covariance (with age as covariate) with post hoc Tukey tests. Correlations
were determined using Pearson correlation coefﬁcient, followed by partial
correlation controlling for age and BMI. For the correlation analyses the
false discovery rate was used to protect against multiple testing. All
values in the text and tables are displayed as mean+SD, unless otherwise
stated. The Statistical Package for the Social Sciences package was used for
all analyses (SPPS, Inc., Chicago, IL, USA). A P-value , 0.05 was
considered signiﬁcant.
Results
Subject characteristics
All women with PCOS displayed oligomenorrhoea/amenorrhoea and
polycystic ovaries, and the majority also had clinical or biochemical
hyperandrogenism [16 (80.0%) among overweight patients with
PCOS and 6 (60.0%) among lean patients with PCOS]. Baseline
characteristics of the study population are shown in Table I. The over-
weight patients with PCOS were younger, had increased TG, FAI and
lower systolic blood pressure than the overweight controls. Other-
wise, there were no differences between overweight patients with
PCOS and overweight control subjects. Because of the difference in
age between groups, subsequent analyses were adjusted for age.
In comparison with lean PCOS patients, overweight patients with
PCOS and overweight control subjects had increased serum concen-
trations of TG, insulin, HOMA-IR and hs-CRP. Likewise, overweight
patients with PCOS and overweight control subjects had higher systo-
lic and diastolic blood pressure than lean PCOS patients. There were
no differences between the three groups in serum concentrations of
IL-18 or CCL2, Table I.
Adipose tissue gene expression
Relative amounts of mRNA for inﬂammatory markers in adipose tissue
from overweight and lean patients with PCOS as well as overweight
controls are displayed in Fig. 1. Overweight patients with PCOS and
overweight control subjects had increased relative amounts of
CCL2, CCR2, TNF-a, IL-10, IL-18, CD14 and CD163, and decreased
........................................................................................
Table I Clinical characteristics of women in a study of
markers of adipose tissue inﬂammation in relation to
PCOS and weight.
Lean
PCOS
patients
n 5 10
Overweight
PCOS
patients
n 5 20
Overweight
controls
n 5 20
Age, years 27.0+4.8
b 29.6+5.1
b 35.1+5.7
BMI, kg/m
2 22.4+2.0
a,b 34.4+4.8 34.5+4.4
Waist circumference,
cm
68+26
a,b 106+13 112+14
Waist-hip ratio 0.77+0.77
a,b 0.91+0.06 0.93+0.09
Glucose, mmol/l 4.5+0.3 5.0+0.5 5.2+1.0
Insulin, mU/l 4.5+1.51
a,b 16.4+12.1 12.6+7.0
HOMA-IR 0.89+0.30
a,b 3.79+3.20 3.08+2.37
hs-CRP, mg/l 1.10+0.99
a,b 4.31+3.16 3.48+4.06
Serum CCL2, pg/ml 352+96 371+118 416+138
Serum IL-18, pg/ml 215+50 331+164 283+118
Serum TG, mmol/l 0.62+0.16
a,b 1.50+0.70
b 1.11+0.38
Serum cholesterol,
mmol/l
4.5+0.90 4.8+1.0 4.7+0.7
Systolic blood
pressure, mmHg
111+10
b 119+11
b 132+10
Diastolic blood
pressure, mmHg
72+9
a,b 80+10 86+9
Serum testosterone,
nmol/l
1.7+0.8 2.4+1.0
b 1.6+0.8
Serum SHBG, nmol/l 49.8+19.7
a 33.4+16.1 37.7+17.7
FAI 5.46+6.38
a 9.12+6.07
b 4.84+3.02
Data are mean+SD.
CCL2, chemokine (C-C motif) ligand 2; CCR2, chemokine receptor 2; IL,
interleukin; TG, triglycerides; hs-CRP, cholesterol high-sensitive C-reactive protein;
HOMA-IR, homeostasis model assessment of insulin resistance; SHBG, sex
hormone-binding globulin; FAI, free androgen index.
aSigniﬁcantly different versus overweight patients with PCOS, P , 0.025–0.001,
one-way analysis of covariance (ANCOVA), adjusted for age.
bSigniﬁcantly different versus overweight control subjects, P , 0.025–0.001,
ANCOVA, adjusted for age.
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lean patients with PCOS (data not shown in ﬁgure for adiponectin
owing to high relative expression, i.e. 12.99+1.80, 8.88+1.97 and
9.56+2.05 for lean and overweight patients with PCOS, and over-
weight control subjects, respectively, P , 0.01 for lean patients with
PCOS versus overweight patients and overweight controls). There
were no differences between overweight patients with PCOS and
overweight controls in levels of adipose tissue mRNA for any of
these inﬂammatory markers. MIF and IL-6 expression did not differ
between groups (IL-6 data not shown owing to very low relative
expression, i.e. 0.03+0.02, 0.05+0.03 and 0.04+0.02 for lean
and overweight patients with PCOS, and overweight controls,
respectively).
When analyses were restricted to PCOS subjects fulﬁlling the
hyperandrogenism criterion (n ¼ 16) the results were unchanged
(data not shown).
Adipose tissue mRNA levels and circulating levels of IL-18 and
MCP-1 were positively correlated (r ¼ 0.44, P , 0.01 and r ¼ 0.37
P , 0.05, respectively).
Relationship between adipose tissue
inﬂammation markers and obesity-related
metabolic disturbances in patients with
PCOS
Among patients with PCOS, the adipose tissue markers of inﬂam-
mation, except for MIF, were correlated with most metabolic risk
markers, including BMI, waist circumference, glucose, insulin,
HOMA-IR, TG and systolic and diastolic blood pressures (Table II).
CCR2, IL-10, IL-18, CD14 and CD163 mRNAs were negatively cor-
related with serum concentrations of SHBG, whereas adiponectin
was positively correlated with SHBG. However, there were no corre-
lations between FAI, testosterone or total cholesterol and the markers
of adipose tissue inﬂammation (data not shown for testosterone and
total cholesterol).
As depicted in Tables II and III, the main explanatory variable for the
adipose tissue inﬂammatory markers in patients with PCOS was BMI.
Following the adjustment for age and BMI (Table III), signiﬁcant posi-
tive correlations only remained between adipose tissue TNF-a
mRNA level and systolic blood pressure, and similarly IL-6 was posi-
tively correlated with insulin and HOMA-IR (data not shown for
FAI). Adiponectin was negatively correlated with TG.
Discussion
This study demonstrates that the gene expression pattern of inﬂam-
mation markers in abdominal superﬁcial subcutaneous tissue is
similar in overweight patients with PCOS and overweight control sub-
jects. Furthermore, this ﬁnding remains when analyses are restricted to
those patients with PCOS who displayed hyperandrogenism. In con-
trast, lean patients with PCOS display lower expression of adipose
tissue inﬂammation markers compared with the two overweight
groups. In concert with this ﬁnding, most of the associations
between markers of adipose tissue inﬂammation and variables of
the metabolic syndrome in patients with PCOS were lost when
adjusted for age and BMI. Thus, overweight or obesity, rather than
the PCOS diagnosis per se appears to be the main explanatory variable
for increased subcutaneous adipose tissue inﬂammation in patients
with PCOS.
Most phenotypes of PCOS—irrespective of degree of obesity—are
hallmarked by a combination of androgen excess and insulin resist-
ance. While the association with type 2 diabetes is well established,
the precise CVD risk in PCOS women is still unclear, in part
because there are no, or few, longitudinal studies examining cardiovas-
cular events and/or mortality. However, biochemical hyperandrogen-
ism is associated with CVD risk factors in young as well as middle-aged
and post-menopausal healthy women (Sowers et al., 2005; Sutton-
Tyrrell et al., 2005; Coviello et al., 2006; Shaw et al., 2008) and in post-
menopausal women, hyperandrogenism has also been associated with
CVD events (although not independently of BMI) (Rexrode et al.,
2003). Previous studies have indicated that serum concentrations of
inﬂammatory markers, such as MCP-1 (i.e. CCL2) and CRP, are
increased in overweight patients with PCOS compared with weight-
matched controls (Gonzalez et al., 2009), and that the inﬂammatory
status is correlated with levels of hyperandrogenism (Glintborg
et al., 2009; Gonzalez et al., 2009). Other studies have failed to
display any differences between overweight controls and overweight
patients with PCOS in terms of circulating TNF-a and IL-6
(Olszanecka-Glinianowicz et al., 2007). In contrast with previous
studies of inﬂammatory markers in PCOS patients, we were not
able to conﬁrm prior ﬁndings of increased circulating levels of
hs-CRP, CCL2 and IL-18 in overweight PCOS patients, presumably
because our study was powered primarily for the adipose tissue
mRNA levels and not for the circulating levels of inﬂammatory
markers. Similarly, we were unable to demonstrate a correlation
between adipose tissue mRNA levels for inﬂammatory markers and
FAI or testosterone. However, in line with previous studies SHBG,
as an indirect measure of androgenicity and insulin resistance,
Figure 1 Levels of mRNA for inﬂammatory substances
(mean+SD) in abdominal superﬁcial subcutaneous adipose tissue
from lean patients with PCOS (white bars, n ¼ 10), overweight
patients with PCOS (dashed bars, n ¼ 20) and overweight control
subjects (black bars, n ¼ 20). Levels of mRNA are relative to the
RPLP0 gene, which was used to normalize data. CCL2, CCR2, macro-
phage MIF, TNF-a.* P , 0.05, **P , 0.01 and ***P , 0.001, one-way
analysis of covariance, adjusted for age, with post hoc Tukey tests.
Adipose tissue inﬂammation in polycystic ovary syndrome 1481was negatively correlated with most of the inﬂammatory markers
(Glintborg et al., 2009; Gonzalez et al., 2009).
Although most studies on PCOS report that obese women with
PCOS are more insulin resistant than control obese women, there
was no difference in our present study. The reason for this is
unclear but may involve the fact that the overweight women with
PCOS did not differ in waist circumference compared with controls.
When women with PCOS are compared with control women
matched for abdominal adiposity, the difference in insulin resistance
between the groups is much less marked than if the two groups are
matched for BMI (Holte et al., 1994). It is also possible that our rela-
tively small comparative study was unable to reveal true differences in
insulin sensitivity. The fact that, based upon waist circumference
measurements and waist-hip ratio, obese women with PCOS and
obese controls did not differ in this study goes against the notion
that anovulatory women build up more truncal-abdominal fat.
However, data from recent studies utilizing advanced imaging tech-
niques are ambiguous. Using magnetic resonance imaging, Barber
and colleges found that overweight PCOS cases and BMI/fat mass-
matched controls were indistinguishable with respect to distribution
of fat within visceral, abdominal subcutaneous and gluteofemoral sub-
cutaneous fat depots (Barber et al., 2008). Furthermore, by use of
computer tomography, it was recently demonstrated that obese
women with PCOS only have a modest, but signiﬁcant, increase in
visceral fat compared with BMI/fat mass-matched non-PCOS
women (Hutchison et al., 2011). Notably, these studies (Barber
.............................................................................................................................................................................................
Table II Bivariate correlations between mRNA level for CCL2, CCR2, MIF, TNF-a, IL-6, IL-10, IL-18, CD14, CD163
(monocyte/macrophage markers) in adipose tissue and adiponectin and selected anthropometric/metabolic variables in
all women with PCOS (n 5 30).
Age BMI Waist Glucose Insulin HOMA-IR TG Systolic
blood
pressure
Diastolic
blood
pressure
FAI SHBG
CCL2 0.01 0.52** 0.42* 0.55** 0.34 0.44* 0.33 0.52** 0.28 20.08 20.25
CCR2 0.08 0.52** 0.42 0.59** 0.50** 0.50** 0.50** 0.12 0.30 0.00 20.50**
MIF 0.07 20.08 20.03 0.02 0.02 0.02 0.06 20.07 20.18 20.10 0.09
TNF-a 0.40 0.55** 0.48* 0.58** 0.42* 0.41 0.46* 0.65** 0.52** 20.18 20.23
IL-6 0.01 0.40 0.55** 0.51** 0.63** 0.64** 0.54** 0.25 0.24 20.16 20.19
IL-10 0.22 0.78** 0.75** 0.69** 0.52** 0.52* 0.59** 0.56** 0.54** 0.13 20.49*
IL-18 0.31 0.76** 0.73** 0.67** 0.54** 0.54** 0.57* 0.47* 0.55** 0.00 20.38
CD14 0.12 0.78** 0.75** 0.67** 0.55** 0.55** 0.56** 0.53** 0.58** 0.04 20.41
CD163 0.15 0.77** 0.68** 0.61** 0.51* 0.50* 0.54* 0.52* 0.55** 0.09 20.45*
Adiponectin 20.08 20.61** 20.57** 20.50** 20.58** 20.57** 20.65** 20.22 20.32 20.16 0.54*
MIF, macrophage migration inhibitory factor; TNF-a, tumour necrosis factor-a .
*P , 0.025 and **P , 0.005, Pearson correlation coefﬁcient.
.............................................................................................................................................................................................
Table III Partial correlations (controlling for age and BMI) between mRNA level for CCL2, CCR2, MIF, TNF-a, IL-6,
IL-10, IL-18, CD14, CD163 in adipose tissue and adiponectin and selected anthropometric/metabolic variables in all
patients with PCOS (n 5 30).
Waist Glucose Insulin HOMA-IR TG Systolic blood
pressure
Diastolic blood
pressure
SHBG
CCL2 0.16 0.06 0.02 0.04 0.12 0.39 20.13 0.19
CCR2 20.02 0.41 0.22 0.23 0.26 20.20 20.06 20.29
MIF 0.04 20.06 0.19 0.17 0.15 0.04 20.08 0.01
TNF-a 0.07 0.17 0.19 0.19 0.29 0.50* 0.13 0.15
IL-6 0.36 0.36 0.48* 0.51* 0.39 0.11 20.04 0.02
IL-10 0.38 0.18 20.12 20.13 0.22 0.35 0.07 20.14
IL-18 0.31 0.18 0.03 0.01 0.21 0.23 0.19 20.06
CD14 0.33 0.15 20.12 20.11 0.09 0.34 0.20 0.12
CD163 0.18 0.08 20.15 20.13 20.00 0.35 0.19 0.00
Adiponectin 20.18 20.06 20.30 20.25 20.46* 0.01 0.01 0.36
*P , 0.025, partial correlation, controlling for age and BMI.
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subjects, which may explain the discrepancy from previous studies
where mainly lean subjects were included (Yildirim et al., 2003). Con-
cerning visceral adiposity and the close link to metabolic risk, it is
unfortunate that we had only biopsies from the abdominal superﬁcial
subcutaneous adipose tissue depot. It has recently been reported that
the different adipose tissue depots have different proﬁles of inﬂamma-
tory markers (Harman-Boehm et al., 2007; Huber et al., 2008;
Poulain-Godefroy et al., 2008), and genomic and proteomic proﬁling
studies of morbidly obese PCOS omental adipose tissue have revealed
changes in components of several biological pathways (Corton et al.,
2007, 2008). Consequently, there might be differences in the inﬂam-
matory status of visceral adipose tissue in overweight PCOS versus
weight-matched controls. However, it is not likely that the visceral
tissue directly would account for the increased circulating concen-
trations of plasma cytokines and chemokines. Only a limited number
of adipose-derived mediators are actually released into the circulation
in amounts sufﬁcient to result in the increased systemic levels which
are associated with obesity (Dahlman et al., 2005; Murdolo et al.,
2007). Indirectly, however, the portal drainage of visceral fat provides
direct hepatic access to free fatty acids and adipokines that may acti-
vate hepatic immune mechanisms with production of inﬂammatory
mediators, such as CRP (Despres and Lemieux, 2006). Further
studies of adipose tissue depot-speciﬁc inﬂammation in relation to cir-
culating levels of inﬂammatory markers in larger cohorts of women
with PCOS are thus warranted.
Supportforapossiblecausalrelationshipbetweenobesity-associated
low-gradeinﬂammationandmetabolicimpairmentisgainedfromepide-
miological data indicating an association of markers of systemic inﬂam-
mation (i.e. CRP, IL-6) with insulin resistance and future risk for
development of diabetes type 2 (Pradhan et al., 2001). In agreement
with previous studies, we found a pronounced effect of increased
body mass on adipose tissue expression of chemokines,
pro-inﬂammatory cytokines and markers of inﬂammation (Hotamisligil,
2003; Bruun et al., 2007; Huber et al., 2008; Shakeri-Manesch et al.,
2009),whereasoverweightpatientswithPCOSdidnotdifferfromover-
weight controls in this respect. We showed that MIF mRNA, however,
was not inﬂuenced by fat mass in agreement with data from our labora-
tory where MIF expression in subcutaneous fat depots from white
women was unaffected by fat mass (Evans et al., 2011). Skurk et al.
(2005) reported that secretion of MIF from isolated human subcu-
taneous adipocytes correlated with BMI, seemingly in conﬂict with our
data.Importantly,themajorityofMIFsecretedfromadiposetissueorig-
inates from non-fat cells in obesewomen (Fain et al., 2006) and it is also
likely that the adipocyte isolation and culturing procedure per se can
inﬂuence the secretion pattern (Ruan et al., 2003). Similar to MIF, we
found no effect of fat mass on adipose tissue IL-6 mRNA. Although a
minority of the body’s circulating IL-6 is derived from adipose tissue
(Mohamed-Ali et al., 1997; Weisberg et al., 2006), secretion from
adipose tissue and circulating IL-6 levels are suggested to be a function
of the degree of fat mass (Kern et al., 2001). However, since we did not
measure IL-6 secretion, this issue should be investigated further.
Several pro-inﬂammatory cytokines are elevated in parallel with
many metabolic risk markers, whereas the anti-inﬂammatory and
adipocyte-speciﬁc hormone adiponectin is consistently lower (Spran-
ger et al., 2003). In agreement with this, our lean patients with
PCOS had higher levels of mRNA for adiponectin versus the
overweight groups. Adiponectin exerts anti-inﬂammatory effects on
adipocytes primarily via inhibition of the nuclear factor lB pathway
(Ajuwon and Spurlock, 2005). As a result, release of a number of
pro-inﬂammatory cytokines (e.g. MCP-1, IL-6) by adipocytes is sup-
pressed (Ajuwon and Spurlock, 2005; Dietze-Schroeder et al.,
2005). Expression of the anti-inﬂammatory cytokine IL-10, on the
other hand, was lower in the lean group which has been reported pre-
viously (Juge-Aubry et al., 2005). The fact that anti-inﬂammatory cyto-
kine IL-10 is upregulated in adipose tissue from obese humans
suggests that adipose tissue may produce anti-inﬂammatory cytokines
with the potential to limit the overall pro-inﬂammatory response com-
monly seen in obesity.
It is possible that adipokine secretion pattern might inﬂuence blood
pressure parameters and in this respect, most focus has been on
endocrine factors, such as leptin and adiponectin, which may activate
and inhibit, respectively, the sympathetic nervous system (reviewed in
Mathieu et al., 2009). In this study, adipose tissue TNF-a (mainly auto-
crine/paracrine action) correlated with systolic blood pressure. Since
TNF-a may act on immune cells and induce local and systemic inﬂam-
mation, endothelial as well as vascular function might be altered.
Indeed, systemic TNF-a has been suggested as an independent risk
factor for elevated blood pressure in apparently healthy subjects (Bau-
tista et al., 2005). Notably, the contribution of adipose tissue TNF-a
to the circulation has not been fully resolved and there is only a
modest elevation of serum TNF-a concentrations in obesity
(Hauner, 2005).
There are a number of limitations in this study. The study included a
limited number of participants, which presumably is the reason why a
difference in circulating levels of inﬂammatory markers was not
detected. Furthermore, control subjects were signiﬁcantly older than
the patients with PCOS, but we adjusted for this age difference, and
this appears not to have affected the primary outcome variables: as
our study did not include a lean control group, we are unable to deter-
mine whether lean patients with PCOS differ in adipose tissue
expression of inﬂammatory markers from weight-matched controls.
Furthermore, the inclusion of a lean control group would have
enhanced our understanding of how adipose tissue inﬂammation is
inﬂuenced by hyperandrogenism and PCOS. Another limitation, dis-
cussed above, is that only adipose tissue biopsies from one anatomical
location were available for study.
In conclusion, fat mass rather than a PCOS diagnosis per se seems to
be the main determinant of increased inﬂammatory markers in subcu-
taneousadipose tissue.Further studies investigatingthedifferentclinical
phenotypes of PCOS in terms of cardiovascular risk are warranted.
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